{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/rheumatoid-arthritis/diagnosis/investigations-for-suspected-ra/","result":{"pageContext":{"chapter":{"id":"5de822df-3081-5ed6-a21b-e3e2925436bd","slug":"investigations-for-suspected-ra","fullItemName":"Investigations for suspected RA","depth":2,"htmlHeader":"<!-- begin field 70894532-4ee6-4caa-87aa-e8a0d3a8e043 --><h2>What investigations are necessary for suspected rheumatoid arthritis?</h2><!-- end field 70894532-4ee6-4caa-87aa-e8a0d3a8e043 -->","summary":"","htmlStringContent":"<!-- begin item 5c8f3fc8-c912-44ee-8759-707f4086bcb0 --><!-- begin field ed36f873-18ac-4134-a3a1-0df6e6b8b610 --><ul><li><strong>There is no specific diagnostic test for rheumatoid arthritis (RA), the diagnosis is clinical. <a class=\"topic-reference internal-reference\" href=\"/topics/rheumatoid-arthritis/management/confirmed-ra/#referral-for-surgery\">Refer</a> all people <a class=\"topic-reference internal-reference\" href=\"/topics/rheumatoid-arthritis/diagnosis/when-to-suspect-ra/\">suspected</a> of having RA for specialist assessment.</strong></li><li><strong>If RA is suspected clinically, investigations are not necessary in primary care, however, consider the following tests to speed up the diagnostic process:</strong><ul><li>Offer to carry out a blood test for rheumatoid factor — this is present in 60–70% of people with RA.</li><li>Consider measuring anti-cyclic citrullinated peptide (anti-CCP) antibodies in people if they are negative for rheumatoid factor — these are found in about 80% of people with RA.</li><li>Arrange X-ray of the hands and feet — these help with diagnosis and determination of disease severity.</li></ul></li><li><strong>Consider the following tests to speed up the diagnostic process, and to act as a baseline measure prior to <a class=\"topic-reference internal-reference\" href=\"/topics/rheumatoid-arthritis/management/confirmed-ra/#drug-treatments\">treatment</a>: </strong><ul><li>Full blood count, renal and liver function tests — these will help guide treatment and identify any relevant comorbidities.</li><li>C-reactive protein or erythrocyte sedimentation rate — inflammatory markers are usually, but not always, elevated in RA (up to 40% of people with RA may have normal levels). </li><li>Ultrasound or magnetic resonance imaging (MRI) of joints — depending on local policy and availability. </li></ul></li><li><strong>Do not let investigations delay a referral for clinically suspected RA.</strong> </li></ul><!-- end field ed36f873-18ac-4134-a3a1-0df6e6b8b610 --><!-- end item 5c8f3fc8-c912-44ee-8759-707f4086bcb0 -->","topic":{"id":"80425c66-11ed-5a54-aecf-455f339cb0cd","topicId":"d9596563-d663-48ca-8d6a-4ddeb263b46e","topicName":"Rheumatoid arthritis","slug":"rheumatoid-arthritis","lastRevised":"Last revised in April 2020","chapters":[{"id":"e5b4cb7c-c830-59e0-a369-a8151bd28e7c","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"28d53d37-f5b2-5ab0-bd6f-6c6858fc63e4","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"8eb76d85-83a8-5bb1-be89-15a9e86def8d","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"7eba8b39-2fb0-52b0-8988-5d108c1720fa","slug":"changes","fullItemName":"Changes"},{"id":"add57644-4b68-5377-b8ce-b0cc395570f0","slug":"update","fullItemName":"Update"}]},{"id":"62d68b4b-4522-5afb-88fe-48b87fc31a2d","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f9fe7005-bf48-5a4e-bc7c-08550e792a18","slug":"goals","fullItemName":"Goals"},{"id":"cc0b2b43-25e2-5936-ad94-217419fd0126","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6a0fead6-ca32-5399-9b1b-22b31fc0c765","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f76001a5-99f4-5086-bc05-c1cd7535aab0","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"fb29501f-d465-5652-b659-ffb4e5c8e928","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"3181265d-dee9-5587-974d-b4bae95c10ee","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"167941e5-411a-5afd-94af-8e7725b24b1a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"bb48f4e9-23c4-5828-bccb-666f4dbc512d","slug":"definition","fullItemName":"Definition"},{"id":"06cc7595-3f6c-59d6-929b-964159afde4d","slug":"prevalence-incidence","fullItemName":"Prevalence and incidence"},{"id":"8fb1fc93-039a-5d6b-a86d-aeb61578f11d","slug":"complications","fullItemName":"Complications"}]},{"id":"e352008d-7a0c-55ba-b778-c6218ef4ef69","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"b9d257ab-0ebb-52bf-908a-8ebebe6c550c","slug":"when-to-suspect-ra","fullItemName":"When to suspect RA"},{"id":"25d80dc3-ea8a-5560-8a0b-3a64b87c5690","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"5de822df-3081-5ed6-a21b-e3e2925436bd","slug":"investigations-for-suspected-ra","fullItemName":"Investigations for suspected RA"}]},{"id":"6f1e7941-f462-5d64-8822-8328310b81b9","fullItemName":"Management","slug":"management","subChapters":[{"id":"2ed609a5-1052-56f5-b263-63d4e5325949","slug":"suspected-ra","fullItemName":"Scenario: Suspected RA"},{"id":"0ba5ec6e-3f0f-5157-8e24-55ef24b2cfe9","slug":"confirmed-ra","fullItemName":"Scenario: Confirmed RA"},{"id":"c490cb4d-f228-5c81-b9f2-0ac419b6d60a","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"13cb1ed1-b962-5e8a-88c8-8b7185af06df","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"e875cc8d-258b-5535-9d34-40f03cb150c7","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"9b45cf27-1cfb-591d-a936-5e49910f88ac","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"93bd3cb0-31a7-5acf-bc5f-8858b54e466b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"a24a6436-a685-5277-8c22-524ebe895154","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4258a438-16bd-591d-bd95-5d6a682e1696","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"58298e48-e237-5259-b79b-da11e96f0a4e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"6c1abdea-39c1-5537-8e4f-6e6ff3a71736","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"e352008d-7a0c-55ba-b778-c6218ef4ef69","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"abf1a904-782e-5f77-9542-a583a6ca2637","slug":"basis-for-recommendation-f90","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field ea7c8dac-7e1e-46a4-b77a-4e72267a6a31 --><h3>Basis for recommendation</h3><!-- end field ea7c8dac-7e1e-46a4-b77a-4e72267a6a31 -->","summary":null,"htmlStringContent":"<!-- begin item f90894a9-6a4f-45c1-a5db-da21ccabd61a --><!-- begin field dbdc77f4-4cfd-4f5a-a3da-3f112183e53c --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guidelines <em>Rheumatoid arthritis in adults: management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/rheumatoid-arthritis/references/\">NICE, 2018a</a>] and <em>Rheumatoid arthritis: national clinical guideline for management and treatment in adults</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rheumatoid-arthritis/references/\">National Collaborating Centre for Chronic Conditions, 2018</a>], the British Medical Journal (BMJ) best practice guide <em>Rheumatoid arthritis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rheumatoid-arthritis/references/\">BMJ, 2018</a>], expert opinion in narrative reviews <em>Diagnosis and early management of inflammatory arthritis </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/rheumatoid-arthritis/references/\">Ledingham, 2017</a>], <em>Diagnosis and management of rheumatoid arthritis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rheumatoid-arthritis/references/\">Wasserman, 2011</a>], and what CKS consider good clinical practice. </p><h4>Ultrasound and MRI [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rheumatoid-arthritis/references/\">National Collaborating Centre for Chronic Conditions, 2018</a>]</h4><ul><li><p>There is evidence to suggest that ultrasound and magnetic resonance imaging (MRI) scans are superior to clinical examination in the detection of synovitis, and that they are more sensitive to the presence of erosions and other early inflammatory and damage signs than conventional X-rays. However, NICE states that as the long-term significance of these findings is unknown and because the availability may be limited, clinician examination remains the gold standard for diagnosis of synovitis.</p></li></ul><!-- end field dbdc77f4-4cfd-4f5a-a3da-3f112183e53c --><!-- end item f90894a9-6a4f-45c1-a5db-da21ccabd61a -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}